Santen Pharmaceutical Overview
- Year Founded
-
1890
- Status
-
Public
- Employees
-
3,968
- Stock Symbol
-
4536
- Investments
-
10
- Share Price
-
$12.53
- (As of Thursday Closing)
Santen Pharmaceutical General Information
Description
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
Contact Information
Website
www.santen.comCorporate Office
- Grand Front Osaka Tower A
- 4-20 Ofuka-cho, Kita-ku
- Osaka, 530-8552
- Japan
Corporate Office
- Grand Front Osaka Tower A
- 4-20 Ofuka-cho, Kita-ku
- Osaka, 530-8552
- Japan
Santen Pharmaceutical Stock Performance
As of 12-Nov-2026, Santen Pharmaceutical’s stock price is $12.53. Its current market cap is $4.03B with 322M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $12.53 | $12.57 | $9.85 - $13.96 | $4.03B | 322M | 1.33M | $0.76 |
Santen Pharmaceutical Financials Summary
As of 30-Sep-2026, Santen Pharmaceutical has a trailing 12-month revenue of $1.89B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 3,308,479 | 3,551,662 | 3,073,890 | 3,498,363 |
| Revenue | 1,887,323 | 1,934,809 | 1,967,264 | 2,089,870 |
| EBITDA | 366,925 | 375,319 | 360,706 | 340,121 |
| Net Income | 247,014 | 247,928 | 237,747 | 184,387 |
| Total Assets | 2,658,243 | 2,646,305 | 2,735,034 | 2,878,751 |
| Total Debt | 367,987 | 367,501 | 377,654 | 384,209 |
Santen Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Santen Pharmaceutical Comparisons
Industry
Financing
Details
Santen Pharmaceutical Competitors (1)
One of Santen Pharmaceutical’s competitors is Shionogi, a Corporation company based in Osaka, Japan.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Shionogi | Corporation | Osaka, Japan |
Santen Pharmaceutical Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Santen Pharmaceutical Patents
Santen Pharmaceutical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2026178428-A | Aqueous suspension contained in injection-blown multi-dose eye drop containers. | Pending | 01-Sep-2026 | ||
| JP-2026172840-A | Eye drop aid | Pending | 15-Apr-2025 | ||
| WO-2026182056-A1 | Aqueous composition containing atropine and buffering agent | Pending | 26-Feb-2025 | ||
| WO-2026134309-A1 | Use of cyp46a1 inhibitors to treat eye and associated diseases | Pending | 20-Dec-2024 | ||
| WO-2026121321-A1 | Aqueous atropine‑containing pharmaceutical composition which has been photostabilized and/or prevented from undergoing viscosity reduction | Pending | 06-Dec-2024 |
Santen Pharmaceutical Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Santen Pharmaceutical Investments & Acquisitions (10)
Santen Pharmaceutical’s most recent deal was a Merger/Acquisition with Novartis (Ophthalmology Division). The deal was made on 20-Oct-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Novartis (Ophthalmology Division) | 20-Oct-2025 | Merger/Acquisition | Pharmaceuticals | ||
| NovaSight | 07-Dec-2022 | Later Stage VC | Therapeutic Devices | ||
| Eyevance Pharmaceuticals | 16-Sep-2020 | Merger/Acquisition | Pharmaceuticals | ||
| Twenty Twenty Therapeutics | 14-Aug-2020 | Joint Venture | Diagnostic Equipment | ||
| Ace Vision | 01-Mar-2020 | Later Stage VC | Therapeutic Devices |
Santen Pharmaceutical ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
23.01 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Santen Pharmaceutical Exits (2)
Santen Pharmaceutical’s most recent exit was on 02-Sep-2014 from Clearside Biomedical. The exit was categorized as with 6 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Clearside Biomedical | 02-Sep-2014 | Completed |
|
||
| Advanced Vision Science | 01-Jan-2001 | Merger/Acquisition | Completed |
Santen Pharmaceutical Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Santen Ventures | Emeryville, CA | 2017 |
Santen Pharmaceutical FAQs
-
When was Santen Pharmaceutical founded?
Santen Pharmaceutical was founded in 1890.
-
Where is Santen Pharmaceutical headquartered?
Santen Pharmaceutical is headquartered in Osaka, Japan.
-
What is the size of Santen Pharmaceutical?
Santen Pharmaceutical has 3,968 total employees.
-
What industry is Santen Pharmaceutical in?
Santen Pharmaceutical’s primary industry is Distributors (Healthcare).
-
Is Santen Pharmaceutical a private or public company?
Santen Pharmaceutical is a Public company.
-
What is Santen Pharmaceutical’s stock symbol?
The ticker symbol for Santen Pharmaceutical is 4536.
-
What is the current stock price of Santen Pharmaceutical?
As of 12-Nov-2026 the stock price of Santen Pharmaceutical is $12.53.
-
What is the current market cap of Santen Pharmaceutical?
The current market capitalization of Santen Pharmaceutical is $4.03B.
-
What is Santen Pharmaceutical’s current revenue?
The trailing twelve month revenue for Santen Pharmaceutical is $1.89B.
-
Who are Santen Pharmaceutical’s competitors?
Shionogi is a competitor of Santen Pharmaceutical.
-
What is Santen Pharmaceutical’s annual earnings per share (EPS)?
Santen Pharmaceutical’s EPS for 12 months was $0.76.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
